Flow Cytometry assay shows that Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-1 is 1 μg/mL (Routinely tested).
FACS analysis shows that the binding of Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-1 is 1 μg /mL. The IC50 is 5.5 μg/mL (Routinely tested).
Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, Mouse IgG2a Fc Tag (Cat. No. B71-H52A4) with an affinity constant of 2.72 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Belatacept | LEA29Y; LEA-029; BMS-224818; L104EA29YIg | Approved | Bristol-Myers Squibb Company | Nulojix | United States | Rejection of renal transplantation | Bristol-Myers Squibb Pharma Eeig | 2011-06-15 | Rejection of renal transplantation; Diabetes Mellitus, Type 1; Arthritis, Rheumatoid; Pancreatic neuroendocrine tumors (pNET); Proteinuria; Rejection of organ transplantation; Delayed Graft Function; Rejection in heart transplantation; Kidney Failure, Chronic | Details |
Abatacept | BMS-188667SC; ONO-4164; BMS-188667; ONO-4164SC | Approved | Bristol-Myers Squibb Company | Orencia, 恩瑞舒 | United States | Arthritis, Rheumatoid | Bristol-Myers Squibb Company | 2005-12-23 | Colitis, Ulcerative; Arthritis; Common Variable Immunodeficiency; Uveitis; Cardiovascular Diseases; Asthma; Arthritis, Psoriatic; Sjogren-Larsson Syndrome; Urticaria; Scleroderma, Diffuse; Psoriasis; Takayasu Arteritis; Glomerulosclerosis, Focal Segmental; Anemia, Aplastic; Lupus Erythematosus, Systemic; Shwachman-Diamond Syndrome; Lung Diseases, Interstitial; Multiple Sclerosis; Nephrotic Syndrome; Muscular Diseases; Eye Diseases; Granulomatous Disease, Chronic; Lymphohistiocytosis, Hemophagocytic; Arthralgia; Myocarditis; Leukocyte-Adhesion Deficiency Syndrome; Inflammation; Vitiligo; Anemia, Sickle Cell; Thrombasthenia; Kostmann Syndrome; Crohn Disease; Behcet Syndrome; Graft vs Host Disease; Polychondritis, Relapsing; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Polymyositis; Wiskott-Aldrich Syndrome; Hematologic Diseases; Diabetes Mellitus, Type 1; Multiple Sclerosis, Relapsing-Remitting; Alopecia Areata; Myositis; Dermatomyositis; Giant Cell Arteritis; Immunoglobulin G4 | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
ORCA-010 | ORCA-010 | Phase 2 Clinical | Orca Therapeutics Bv | Prostatic Neoplasms | Details |
Membrane bound ligand T-SIGn virus | NG-348 | Phase 1 Clinical | Neoplasms | Details | |
Belatacept biosimilar (Alphamab) | KN-019 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Rejection of renal transplantation; Arthritis, Rheumatoid | Details |
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio) | Phase 1 Clinical | Beijing Vdjbio Co Ltd | Arthritis, Rheumatoid | Details |
This web search service is supported by Google Inc.